Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
Influenza Monovalent Whole virus adjuvanted vaccine · 1 trial · 1 indication
Geometric mean titers (GMTs) of serum antibodies
| Arm | Type | Description |
|---|---|---|
| H5N1 Formulation 1 Group | EXPERIMENTAL | Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval |
| H5N1 Formulation 2 Group | EXPERIMENTAL | Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval |
| H5N1 Formulation 3 Group | EXPERIMENTAL | Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval |
| H5N1 Formulation 4 Group | EXPERIMENTAL | Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval |
| H5N1 Formulation 5 Group | ACTIVE_COMPARATOR | Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval |
| H5N1 Formulation 6 Group | ACTIVE_COMPARATOR | Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval |
| H5N1 Formulation 7 Group | ACTIVE_COMPARATOR | Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval |
| H5N1 Formulation 8 Group | ACTIVE_COMPARATOR | Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval |
| Name | Type | Description |
|---|---|---|
| Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine | BIOLOGICAL | 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21 |
| Influenza Monovalent Whole virus (H5N1) | BIOLOGICAL | 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21 |
Inclusion criteria: * A male or female between, and including, 18 and 60 years of age at the time of the first vaccination. * Healthy subjects as established by medical history and clinical examination before entering into the study. * If the subject is female, she must be of non-childbearing poten...